MCA
TGTX icon

McGuire Capital Advisors’s TG Therapeutics TGTX Stock Holding History

McGuire Capital Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.57K Sell
65
-194
-75% -$7.94K ﹤0.01% 620
2026
Q1 		$8.6K Hold
259
– – 0.01% 423
2025
Q4 		$7.72K Buy
+259
New +$8.46K ﹤0.01% 453

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

McGuire Capital Advisors's TGTX Position: Q2 2026 in Review

McGuire Capital Advisors reduced its TG Therapeutics (TGTX) stake by 75% in Q2 2026, selling an estimated $7.94K and leaving 65 shares worth $3.57K. The position accounts for ﹤0.01% of the portfolio, ranked #620.

McGuire Capital Advisors first reported a position in TGTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $8.6K in Q1 2026. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • McGuire Capital Advisors held 65 shares of TG Therapeutics worth $3.57K as of Q2 2026.
  • McGuire Capital Advisors sold 194 TG Therapeutics shares in Q2 2026, an estimated $7.94K.
  • TG Therapeutics made up ﹤0.01% of McGuire Capital Advisors's portfolio in Q2 2026, its #620 holding.
  • McGuire Capital Advisors first reported a position in TG Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • McGuire Capital Advisors's TG Therapeutics position peaked at $8.6K in Q1 2026.
  • 431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on McGuire Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.